Tag: oncology research

Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025...

CAR/TCR/TIL Therapies in Oncology Research Service 2025 | An Essential Tool to Navigate the Fast-evolving Cancer Treatment Landscape

Revolutionize your oncology strategy with the CAR/TCR/TIL Therapies in Oncology Analytical Tool. Navigate the fast-evolving cancer treatment landscape, uncovering 236 new therapies and 5,021 events. Gain strategic insight on 2,374 drug programs, with real-time updates, KOL engagement, and innovative opportunities.

Revolutionize your oncology strategy with the CAR/TCR/TIL Therapies in Oncology Analytical Tool. Navigate the fast-evolving cancer treatment landscape, uncovering 236 new therapies and 5,021 events. Gain strategic insight on 2,374 drug programs, with real-time updates, KOL engagement, and innovative opportunities.

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo.,...

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated...

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsOncology research

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Former Pentagon Advisor: “The $2 Stock Sitting on America’s Greatest Untapped Treasure”

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Tag: oncology research

Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™

CAR/TCR/TIL Therapies in Oncology Research Service 2025 | An Essential Tool to Navigate the Fast-evolving Cancer Treatment Landscape

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated...

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us